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Abstract
Summary: The Journal of Genomes and Exomes is a new, peer-reviewed, open-access, online publication whose scope comprises
reporting of high quality genome, exome, and gene panel sequences with attendant, detailed phenotypes. The intent of this journal is to
facilitate comparisons between genome, exome and gene panel sequencing studies in order to assist significance testing of the genotypephenotype associations, particularly those in uncommon genetic diseases. While there is yet to be a consensus regarding these classifications, the definition of an empiric set is helpful in understanding error models. Herein we have suggested structured templates for
submissions and the rationale for the data fields in these templates, as well as examples. The editorial board of the Journal of Genomes
and Exomes is keen to receive feedback regarding these structured templates and welcomes submissions.
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Introduction

The staggering diversity in human genomes is
exemplified by the numerous unique in addition to the
many common genetic features and phenotypes present
in each individual. Genotype-phenotype associations
promise to reveal the basis of many human attributes—
both beneficial and deleterious.1 This is truthful,
despite the hubris of genetic essentialism: the belief
that genes are deterministic of all phenotypes.2,3
The popular concept that biological knowledge is
the product of independent research by an investigator
working in isolation is no longer unrivaled. In other
fields of research, most notably particle physics, the
concept is endangered, and almost extinct. There is
a growing consensus that the sum of the efforts of a
community of investigators working together is much
greater than that of the parts in isolation.4,5 This was
noted several millennia ago by King Solomon the
Wise.7 Within biomedical science, human genome
analysis has been the forerunner of data sharing and
community analysis by virtue of the digital nature
of genetic data, which facilitates standardization,
compilation, searching, and computation.1 This has
been accelerated by massively parallel next generation
sequencing and analysis (NGSA) and systematized
funding by the National Institutes of Health.36,37
Concomitant compilations or searchable,
standardized phenotype descriptions, unfortunately,
have lagged far behind genome compilation. The vast
majority of human genome and exome sequences are
associated either with no phenotypic information or a
single bivariable. Efforts are underway to standardize
phenotype collections,7,8 but as yet have not been
married with NGSA.33
The Journal of Genomes and Exomes is a new
forum for structured reporting of rich phenotypic
data together with corresponding comprehensive
sets of variants culled from high quality NGSA of
genomes, exomes, and gene panels.9 Here we describe
the rationale for a working model of the initial
standardized data formats and minimal descriptors
of human genome sequences and phenotypes for the
Journal as well as provide examples.

Results

The primary goal of standardized reporting of
genome-scale variation and attendant phenotypes
is to allow comparisons to be made seamlessly
32

between studies. In this way, the Journal will facilitate
testing of the significance of genotype-phenotype
associations, particularly those in rare genetic diseases.
The requirements for cancer genomics are somewhat
different and are in development. To achieve the goal
of cross study comparisons, data formats should be
simple, searchable and in common use in order to
allow compilation. Flat files of delimited (eg, comma
or tab separated) values are preferred. Another
prerequisite for data formats is future interoperability
with additional layers of genomic complexity (such
as haplotypes) and phenotypic complexity (such as
quantitative phenotypic descriptions). All datasets
must, of course, be de-identified in compliance with
the Health Information Privacy Act (HIPAA).10 The
determination of an institutional review board (IRB)
regarding whether such datasets constitute research
involving human subjects or ought to be waived
should be noted. If the former, a statement indicating
that the study was approved by an IRB, that informed
consent was obtained from all subjects, and that all
research was done in accordance with the Declaration
of Helsinki, must be included.

G A Metrics

Deep NGSA is an accurate and sensitive tool to identify
and genotype most nucleotide variants at genome
scale. NGSA on an Illumina HiSeq 2000 sequencer
with an average of 36X and 60X aligned coverage of
100 base pairs (bp) accurately reads genotypes ∼95%
and ∼97%, respectively, of the 3,101,788,170 nucleotide
reference genome (the “callable” genome).13 This
was recently recapitulated with 2 × 100 nucleotide
HiSeq 2500 NGSA.11 100 gigabases (GB) of aligned
sequence (average 32X) is becoming a standard for
new, reportable genotypes in short read genomes with
most NGSA technologies.13
Standardized metrics for sequence depth for
exomes are less well established. With singleton 100
nuceotide HiSeq 2000 sequencing of Illumina hybrid
selection-enriched exomes (approximately 62 Mb of
targets), approximately 2% of target nucleotides have
no coverage (C0, Fig. 1A). This proportion does not
change in the range of 5–20 GB of aligned sequences
(Fig. 1A). Fortunately, C0 nucleotides in exome
NGSA are highly reproducible,12 defining a “callable”
exome.13 The proportion of exome nucleotides with
16X coverage (C16), a conservative depth for highly
Journal of Genomes and Exomes 2013:2
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Figure 1. Change in the depth of coverage of the human exome as a function of the amount of aligned sequences.
otes: anels show results of singleton 100 nucleotide HiSeq 2000 sequencing of llumina hybrid selection-enriched exomes (approximately 62 Mb of
targets). (A) n the range of 5–20 GB of aligned sequences, approximately 2% of exome nucleotides have no coverage (C0). (B) There is an approximately
linear increase in exome nucleotides with at least 16X coverage (C16), a conservative depth for highly accurate genotyping, as the amount of aligned
sequence varies between 5–20 GB.

accurate genotyping,12 increases somewhat linearly
over the same range of aligned sequence (Fig. 1B). Also
using these methods, 8 GB of aligned exome sequence
corresponds to approximately 70X average coverage
and C16 for approximately 99% of target nucleotides
(Fig. 1B). Exome capture enrichment is available from
multiple vendors and in multiple versions, all covering
slightly different targets. Numerous studies have
compared depth of coverage and percent of targeted
nucleotides covered across exome enrichment from
different companies and highlight that each lab may
produce may produce different results even with the
same enrichment technology.22–24 Consequently, rather
than recommend a specific amount of sequence required
for each exome enrichment version, we suggest a
minimum average coverage of 70X for targeted regions
and C16 for each variant called. The percent of targeted
nucleotides covered at C16 and C0 should be reported.
Some laboratories apply different coverage minimums
for homozygous and heterozygous variants, albeit tools
such as GATK do not apply simple coverage filters
for calling genotypes, and parameterization is not yet
being standardized between centers.
Journal of Genomes and Exomes 2013:2

Standardized metrics for sequence depth for gene
panels are relatively primitive. The depth of NGSA
coverage for accurate and sensitive genotyping of a
panel comprising 437 recessive disease genes and
1,978,041 nucleotides enriched by hybrid selection
has been extensively evaluated.12 Agilent hybrid
enrichment of these targets, followed by singleton
50 nucleotide Illumina GAIIx or HiSeq 2000 NGSA
to aligned sequence depth of 0.75–2.00 GB,
gave a highly reproducible subset representing
approximately 1% of target nucleotide with C0.12 The
proportion of target nucleotides with 20X coverage
(C20) increased linearly over the same range of
aligned sequence.12 1 GB of sequence corresponded
to C20 for approximately 90% of target nucleotide
and ∼250X average coverage. More recently, we have
evaluated the same metrics for a panel comprising
526 recessive disease genes and 2,158,661
nucleotides (Dinwiddie et al, unpublished). Illumina
hybrid enrichment of these targets, followed by
singleton 100 nucleotide Illumina HiSeq 2000 NGSA
to an aligned sequence depth of approximately
3 GB, gave 0.48% of highly reproducible target
33
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nucleotide with C0. 3 GB of sequence corresponded
to an average coverage of 850X and to C16 for
approximately 98.5% of target nucleotide. 1 GB
(or ∼350X coverage) is suggested as the interim
minimum standard for reportable hybrid selectionenriched panels. Enrichment of targeted panels for
NGSA using multiplexed polymerase reaction should
theoretically yield only cognate amplicons,12 but
the same interim minimum standard for reporting is
desired. Coverage recommendations are much more
difficult to standardize in targeted oncology panels,
since tumor cell populations can be oligoclonal or
polyclonal, differing in somatic mutations.25
NGSA technologies are evolving very rapidly.
Current technologies and protocols result in different
read lengths, raw sequence accuracies, and phasing
errors. It is therefore important to record the methods
with sufficient detail to allow a future understanding
of whether discrepancies between studies were the
result of methodological differences. A minimum set
of NGSA methodological data fields are the sample
preparation (library generation) vendor and version,
enrichment technology vendor and type (hybrid
enrichment or amplicons), sequencing technology
vendor and type (panel, exome, genome), and
sequence type (singleton or paired, read length).
Average sequence quality scores, alignment algorithm,
and parameterization are becoming less material as
NGSA technologies mature, but are desired.

cope of Variant Reporting

100 GB raw genome sequences and 3.1 GB consensus
human genome sequences (or 8 GB raw exome
sequences and 62 Mb consensus exome sequences)
are unwieldy. Provided that the version of the human
reference used for alignment is noted, there is
little rationale at present for retention of reference
nucleotides in most compilations of human genome
sequences. Currently, NGSA cannot reliably assemble
haplotypes over meaningful genomic intervals at
genome scale. When possible, however, retention of
phase information will become very important. At
present, NGSA is limited in its ability to detect copy
number variations (CNV) or structural variations.
Thus, the initial minimal descriptors of human genome
sequences for the Journal will be nucleotide and
polynucleotide substitutions, insertions, and deletions.
The cutoff for the size of callable polynucleotide
34

variants will vary for substitutions, insertions, and
deletions as well as among NGSA technologies.
Typically, in our experience, contiguous substitutions
within a read are limited to a maximum size of about
five nucleotides, insertions to about fifty nucleotides
and deletions to about two kilobases (Dinwiddie et al,
unpublished). However, this is highly dependent on the
alignment and variant detection methods used. In the
future, additional variant categories will be added, as
methods are validated for their identification by NGSA,
genotyping and imputation of pathogenicity (such
as CNV, chromosomal events, regulatory variants,
synonymous variants of phenotypic relevance).

Variant Annotation tandardization

Standards for the annotation of nucleotide variants and
their likely functional consequence(s) are relatively
well established:
• The Variant Call Format (VCF) for nucleotide variant description;
• The Human Genome Variation Society (HGVS)
format for recording the coordinates and
identities of nucleotide variants at the levels
of chromosome, transcript(s), and predicted
protein(s) sequences;14
• For variants at gene loci, the HUGO Gene
Nomenclature Committee (HGNC) nomenclature
for gene names;15
• For variants in monogenic phenotypes, an
American College of Medical Genetics (ACMG)
pathogenicity category16 (Table 1);
• Human Gene Mutation Database (HGMD),17 NCBI
dbSNP, NCBI ClinVar,33 Leiden Open Variation
Database (LOVD),34 and/or MutaDATABASE35
accession numbers, if present;
• For monogenic phenotypes, the Online Mendelian
Inheritance in Man (OMIM) accession number, if
available;
• For phenotypes other than monogenic disorders, a
controlled vocabulary, such as SNOMED CT (Systematized Nomenclature of Medicine) or Human
Phenotype Ontology (HPO) terms;7,8,27,28
• For phenotypes other than monogenic disorders,
in silico prediction of variant consequences,
for example using the ENSEMBL Variant Effect
Predictor, or ANNOVAR with ENSEMBL or
RefSeq/UCSC gene annotations;18–20
Journal of Genomes and Exomes 2013:2
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Table 1. The example of the American College of Medical Genetics (ACMG) categories for description of the pathogenicity
of nucleotide variants in monogenic diseases.
ategory

Description

1

Known to be causative of disease

2

Novel but expected to be causative
of disease

3

reviously unreported; may or may
not be causative of disease

4

robably not causative of disease

5

reviously reported; recognized
neutral variant

riteria
HGMD “disease mutant” OR dbSN “pathogenic” clinical
significance AND allele frequency ,1%
Loss of initiation codon OR premature stop codon OR loss of stop
codon OR whole transcript deleted OR frameshifting indel OR affects
splice donor/acceptor site OR disrupts splicing by deletion causing
coding domain/intron fusion AND allele frequency ,1%
Non-synonymous substition OR in-frame indel OR disruption of
polypyrimidine tract OR overlap with 5′ exonic, %′ flank or 3′ exonic
splice contexts AND allele frequency ,1%
Synonymous variants unlikely to affect splicing, deep intronic
variants, etc
Review of literature and central mutation databases to assess degree
of certainty that variant is not disease causing. For severe recessive
diseases, homozygosity in unaffected individuals is strong negative
evidence; For severe dominant diseases, presence in unaffected
individuals is strong negative evidence; For rare genetic disorders,
allele frequency .1% is strong negative evidence

ote: The exclusion of variants as pathogenic on the basis of allele frequencies greater than 1% is well accepted but not
definitive.

• Where available, the variant allele frequency.
There are several public resources of such
information,31,32 however, allele frequencies
from other populations are welcomed. This
is particularly important since many variants
annotated as causative of uncommon monogenic
diseases have allele frequencies that are too
high to be causative. Allele frequency .1% and
homozygosity in healthy individuals useful for
distinguishing variants annotated as causative of
uncommon monogenic diseases from misannotated
common polymorphisms.21 Known exceptions
exist including Factor V Leiden (frequency
3%–8% in general US and European populations),
Hemoglobin S and C (7.4% and 1.8% in African
Americans, respectively) and hemochromatosis
HFE p.C282Y (11% in European populations);
• For non-synonymous variants, scores predictive
of deleteriousness (such as SIFT, PolyPhen)26
or tests of evolutionary conservation. The use of
multiple prediction tools can yield conflicting
evidence. However, many newer tools are available
(PANTHER, FATHMM, Hansa, nsSNPAnalyzer,
SNPs&GO and MutPred). A recent comparison
suggested that SNPs&GO and MutPred may
be the best of these, and superior to PolyPhen
or SIFT.29,30
Journal of Genomes and Exomes 2013:2

A standardized data format that combines these
elements is shown in Table 2, where individual
variations are rows and descriptors as columns.
The magnitude of variant reporting of this type is
shown in Table 3. Genome, exome and targeted gene
panel NGSA at depths of 120 GB, 8 GB and 3 GB,
respectively, yield, on average, 4,079,138, 87,542
and 8,510 variants, respectively. Since files with
4 million rows are not trivial to search, we suggest
reporting only of gene-associated variants, or variants
that may have a functional consequence (ACMG
Categories 1–3, thus omitting most synonymous and
intronic variants). For causative variants other than
nucleotide substitutions in reports of genetic diseases,
confirmatory studies in trios are requested using
established, traditional methods.

henotypic Description
and tandardization

Rich description of the components of phenotypes is
necessary for meta-analysis of genotype-phenotype
associations. Standardized Human Phenotype
Ontology (HPO) or SNOMED CT (Systematized
Nomenclature of Medicine) terms are becoming the
consensus for this purpose.7,8,27,28 Most SNOMED
CT terms are qualitative clinical findings derived
from human diseases. They have limitations for
35
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Table 2. An example of a standardized format for reporting of nucleotide variants.
hr

Variant
start

Variant
stop

Variant
type

Reference
nucleotide

Variant
nucleotide

19

282753

282753

Substitution

G

A

A 2C

ENST00000269812.1:c.539C.T;
ENST00000434325.1:c.371C.T;
ENST00000327790.1:c.602C.T

19

287970

287971

nsertion

–

T

A 2C

19

288329

288330

nsertion

–

C

A 2C

19

288374

288374

Substitution

T

C

A 2C

19

307037

307037

Substitution

C

T

M ER2

19

308681

308681

Substitution

G

A

M ER2

19

311708

311708

Substitution

A

G

M ER2

19

311787

311787

Substitution

C

G

M ER2

19

312026

312026

Substitution

C

T

M ER2

19

312143

312143

Substitution

T

C

M ER2

ENST00000269812.1:
c.204+49_204+50insA;
ENST00000327790.1:
c.267+49_267+50insA;
ENST00000434325.1:
c.36+49_36+50insA
ENST00000434325.1:
c.-116-159dupG;
ENST00000327790.1:
c.116-159dupG;
ENST00000269812.1:
c.53-159dupG
ENST00000269812.1:
c.53-203A.G;
ENST00000434325.1:
c.-116-203A.G;
ENST00000327790.1:
c.116-203A.G
ENST00000264819.3:
c.1616+82G.A
ENST00000264819.3:
c.1110-16C.T
ENST00000264819.3:
c.984+137T.C
ENST00000264819.3:
c.984+58G.C
ENST00000264819.3:
c.890-87G.A
ENST00000264819.3:
c.889+48A.G

description of certain relevant findings, such as
dysmorphology terms, specific laboratory, pathology,
or imaging findings. In these cases, a parent descriptor
should be used. HPO terms are superior in this regard
and have recently been mapped to the non-structured,
but widely used, terms of the London Dysmorphology
Database. HPO terms also have the advantage that
they are in the public domain. If necessary, additional
detail can be provided in the text. The burden of
phenotype description of this magnitude is important
to assess. Table 4 shows the results of detailed
translation of the medical records of 8 individuals
36

Gene(s)

HGV cD A

with monogenic disorders into SNOMED CT terms.
There was an average of 14 terms per individual
(range 7–21). Material negative findings may also be
added. A model for a standardized data format that
combines these elements is shown in Table 4.
Ideally phenotypic descriptions of genetic diseases
would include pedigrees. Illustrations of pedigrees,
such as progeny, should be provided, or at least the
initial rows of the phenotypic description describe
the sample label, accession number, gender, clinical
status, accession number(s) of sample(s) from related
individual(s), relationships between those samples,
Journal of Genomes and Exomes 2013:2
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HGV protein

AA
change

BLO UM

Impact

Genotype

db
accession

MH allele
frequency

Classification

ENS 00000388565.1:
p.Ala124Val;
ENS 00000269812.1:
p.Ala180Val;
ENS 00000329697.1:
p.Ala201Val

A.V

0

Nonsynonymous

2

rs1138439

126/651

4

2

rs61624925

119/651

4

2

rs35895757

32/651

4

2

rs12981067

34/651

4

1

rs72982402

33/651

4

1

rs59415447

2/651

4

1

rs72984427

33/651

4

1

rs111820777 35/651

4

1

rs60667274

33/651

4

2

rs10416918

152/651

4

otes: Variant characteristics are listed as columns. Variants are rows.
Abbreviations: Chr, chromosome; Ref, reference; HGVS, Human Genome Variation Society.

summary of phenotype (OMIM), and primary
causative locus (HGNC).
In the future it will be desirable to add modifiers
to the terms, such as age of onset, frequency, severity,
duration, complications, and outcomes. It will also
be very important to add treatments and responses to
treatments. It is envisaged that these innovations will
be added in time.

Discussion

Genomic medicine is a new, structured approach to
disease discovery, diagnosis, and management that
Journal of Genomes and Exomes 2013:2

prominently features NGSA.4 Over the next several
years, genomic medicine is anticipated to discover
the genes that underpin ∼3500 Mendelian disorders
of unknown cause. It will also identify genotypephenotype relationships and on an unparalleled scale.
In addition, it promises to deliver simultaneous,
comprehensive differential diagnostic testing of
likely genetic illnesses at time of presentation,
accelerating molecular diagnosis, increasing
rates of ascertainment, minimizing duration of
empiric treatment, and time-to-genetic counseling.
In the longer term, genomic medicine will help
37

38

equencing
type

Targeted panel
Targeted panel
Targeted panel
Targeted panel
Targeted panel
Exome
Exome
Exome
Exome
Exome
Genome
Genome
Genome
Genome
Genome
Targeted panel
Exome
Genome

ample

UDT1
UDT2
UDT3
UDT173
UDT4
CMH001
CMH002
CMH006
CMH007
CMH064
CMH064
CMH076
UDT2
UDT173
CMH184
Average
Average
Average

9,090
8,922
8,216
7,142
9,181
91,119
93,542
100,761
92,566
109,720
3,985,315
4,497,940
4,014,036
3,976,271
3,922,130
8,510
97,542
4,079,138

Total
variants
8,943
8,744
8,031
6,980
8,962
88,990
91,368
98,548
90,471
106,982
1,869,515
2,098,886
1,888,650
1,859,095
1,840,738
8,332
95,272
1,911,377

Gene-assoc.
variants
486
516
205
123
440
2,870
2,881
3,965
3,768
4,202
1,249,633
1,479,793
691,123
668,922
516,549
354
3,537
921,204

Variants with allele
frequency .1%
(n = 662)
4
5
2
0
2
14
11
6
5
14
24
19
22
15
9
3
10
18

at. 1
variants
0
1
0
0
0
16
25
27
17
26
260
281
292
265
93
0
22
238

at. 2
variants
44
42
31
9
32
417
393
474
438
451
1,446
1,930
2,647
1,339
844
32
435
1,641

at. 3
variants
438
468
172
114
406
2,423
2,452
3,458
3,308
3,711
1,247,903
1,477,563
688,162
667,303
515,612
320
3,070
919,309

at. 4
variants

9
9
9
5
14
12
15
12
14
23
9
7
14
12
17
9
15
12

Mis-annotated
as disease causative
variants ( at. 5)

Table 3. Nucleotide variants yielded by genome, exome and targeted gene panel NGSA at depths of 120 GB, 8 GB and 3 GB, respectively, and categorization according to likelihood of being causative of genetic disease.
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henotype status
OM M D
Causative gene
Related other sample(s)
Relationship(s) with other
samples
Gender
Sequencing scope
GB sequence aligned
Read hred score . 30 (%)
Sequence type (HiSeq)
Aligner
Read length (nucleotides)
Average coverage
Ataxia
Hypotonia
Gait disturbance
Dysarthria
Fatigue
Cerebellar atrophy
Chorea
Dysmetria
Decreased deep tendon
reflexes
Developmental delay
Delayed speech development
Hip dysplasia
Cryptorchidism
Loose skin
Hyperextensible joints
Scoliosis
Syndactyly
Macrocephaly
Frontal bossing
Low set ears
Very low birth weight
Tremor
Epilepsy
Gynecomastia
es planus
Agenesis corpus callosum
Colpocephaly
Obesity

ample feature

Journal of Genomes and Exomes 2013:2

1
1
1
1
1
1
1
1
1
0
0

248290002
229721007
52781008
204878001
58588007
298203008
298382003
373413006
19410003
90145001
95515009
276611006
26079004
84757009
4754008
53226007
5102002
253160006
414916001

1
1

1
1
1
1
0
1
1
0
1

F
E
14
nk
2000
GSNA
100

F
E
14
nk
2000
GSNA
100

MH002
A
208920
606350
CMH001
Sibling

MH001
A
208920
606350
CMH002
Sibling

20262006
398152000
22325002
8011004
84229001
371313002
271700006
32566006
37280007

OM D term

MH006

1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
0
0
0
1

0

M
E
10
nk
2000
GSNA
100

A
612940
179035
CMH007
Sibling

Table 4. An example of a standardized format for reporting of phenotypes.

1
0
1
1
1
1
0
1
0
1
1
1
1
0
1
1
1
1
0

1

M
E
19
nk
2000
GSNA
100

A
612940
179035
CMH006
Sibling

MH007

0

F
E
27
nk
2000
GSNA
2 × 130

A
614171
604310
-

09_956

0
1

F
G
113
91
500
ELAND
2 × 100

A
614498
614506
-

MH172

M
G
137
90
2500
ELAND
2 × 100

A
609004
CMH185
Sibling

MH184

M
G
117
93
2500
ELAND
2 × 100

1

1

1
1

M
E
13
nk
2000
GSNA
100
104
1

A
607694
614258
-

MLD1

(Continued)

A
609004
CMH184
Sibling

MH185

Clinical genome variant reporting

39

40
MH007
1
1
1
1
1
1
1

09_956

1
1
1

7484005
414403008
19373007
246768008
34187009
125495003

1
1
1
1
1
1

30288003
70142008
204342004
83330001
43876007
27637000
67278007
253315002

1
1

MH172

111323005

1
1
1
1

MH006

17268007
56731001
86854008
36649002
399216004

MH002

1
1
1
1
1
1
1
1
1

MH001

230456007
204317008
111287006
32958008
249321001
389087006
48867003
246799009
282038006

15890002
563001
108365000
302215000
84828003
3239007
428875002
271611007
169887003
168092006

OM D term

otes: ndividuals are shown as columns. henotypes are rows.

Albinism
Nystagmus
Skin infection
Thrombocytopenia
Leukopenia
Lymphocyte disorder
Recurrent infection
Small head
Birth length # 3rd centile
Meconium stained amniotic
fluid
Status epilepticus
atent foramen ovale
Tricuspid valve regurgitation
Micrognathia
Abnormal shape of nose
Hypoxemia
Bradycardia
Upslanted palpebral fissures
Congenital abnormality
of external ear
Clinodactyly
ncreased muscle tone
Hyperreflexia
Clonus
Dextro transposition
of the great arteries
Total anomalous
pulmonary venous return
Ventricular septal defect
Atrial septal defect
ulmonary valve atresia
atent ductus arteriosus
Situs inversus
Dextrocardia
ulmonary valve stenosis
Azygous continuation
of the inferior vena cava
Double outlet right ventricle
Hernia
External ophthalmoplegia
Hypometric saccades
High myopia
Dysmyelination

ample feature

Table 4. (Continued)
MH184

1

1
1

0

1

0

MH185

1
1
1
1
1

1

MLD1
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pharmacogenetically-informed treatment regimens
to be implemented.5–7 Lastly, it will increasingly
provide molecular diagnoses and potential drug/
dosing selections that could not have been ascertained
by conventional approaches by virtue of pleiotropic
clinical presentation and genetic heterogeneity.8–11
This is anticipated to transform the diagnosis and
treatment of genetic diseases from phenotypedriven, and genotype-assisted, to genotype-driven
and phenotype-assisted.12
The imminence of genomic medicine has been
substantially hastened by inexpensive sequencing of
exomes (all protein coding exons) and targeted gene
panels.5,6,8,10,17,20–22 Exomes are about ten-fold less
costly than whole genomes. Targeted gene panels, in
turn, are less costly than whole exomes. In addition,
their interpretation and, thus, actionability are much
simpler. Besides the discovery and clinical testing of
genetic disease and pharmacoligically relevant genes,
these technologies are also expanding the applicability of sequence analysis. Examples include oligogenotype-phenotype relationships, such as epistasis, and
ascertainment of the breadth of clinical and genetic
heterogeneity in diseases.
The Journal of Genomes and Exomes seeks to
assist in the implementation of genomic medicine by
scalable reporting of high quality genome, exome,
and gene panel sequences with attendant, detailed
phenotypes. Through such reports, the Journal seeks
to be an international forum for community-based
confirmation or rebuttal of preliminary genotypephenotype relationships by requiring the submission
of supplementary, structured information in a flat file
format. Herein we have described the initial structured templates for submission of such information,
the rationale for these templates and examples. The
Journal of Genomes and Exomes is keen to receive
feedback regarding these structured templates and
examples. This is intended to be a responsive community resource. The greater the number of high
quality exomes and genomes we publish, the more
valuable this resource for discoveries and refinements
in genomic medicine will be.
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